Soviero Asset Management’s Definium Therapeutics DFTX Stock Holding History

Soviero Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-140,000	Closed	-$2.65M	–	71
2026 Q1	$2.65M	Sell	140,000 -10,000	-7%	-$170K	1.32%	37
2025 Q4	$2.01M	Buy	+150,000	New	+$1.86M	0.96%	50

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Soviero Asset Management's DFTX Position: Q2 2026 in Review

Soviero Asset Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 140,000 shares — an estimated $2.65M sold.

Soviero Asset Management first reported a position in DFTX in Q4 2025 and held it in 2 quarters. The position peaked at $2.65M in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Soviero Asset Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Soviero Asset Management sold 140,000 Definium Therapeutics shares in Q2 2026, an estimated $2.65M.
Soviero Asset Management first reported a position in Definium Therapeutics in Q4 2025 and held it in 2 quarters.
Soviero Asset Management's Definium Therapeutics position peaked at $2.65M in Q1 2026.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Soviero Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.